Medexus Pharmaceuticals Schedules First Quarter Fiscal 2021 Conference Call
August 05, 2020 08:30 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that it plans to host a conference call at 8:00 AM...
Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Federal/Provincial/Territorial Public Drug Plan Formularies
July 09, 2020 08:30 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, July 09, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that Triamcinolone Hexacetonide Injectable...
Medexus Pharmaceuticals Reports Record Revenue of $25.6 Million and $4.2 Million of Adjusted EBITDA* for the Fourth Quarter of Fiscal 2020
June 22, 2020 17:15 ET
|
Medexus Pharmaceuticals Inc
Transformative acquisition of IXINITY® completed February 28, 2020 Fiscal 2020 Metoject® unit market demand increased 96%;Rupall™ unit market demand increased 61%; andRasuvo® unit market demand...
Medexus Pharmaceuticals Schedules Fiscal Year 2020 Conference Call
June 17, 2020 09:15 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, June 17, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM...
Medexus to Present at the Virtual Summer Summit on June 10th
June 03, 2020 09:00 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and MONTREAL, June 03, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today announced that it will be presenting at...
Medexus Provides an Update on the IXINITY® Acquisition and its Overall Business in the COVID-19 Environment
May 22, 2020 08:51 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and MONTREAL, May 22, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today provided an update on its business in...
Medexus Announces US$20 Million Asset-Based Credit Facility and Repays US$10 Million of its Term Loan
May 07, 2020 17:00 ET
|
Medexus Pharmaceuticals Inc
TORONTO, CHICAGO and MONTREAL, May 07, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today announced that the Company has entered...
Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Public Reimbursement in Canada
April 08, 2020 08:30 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, April 08, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that the pan-Canadian Pharmaceutical Alliance...
Medexus to Present at the Spring Investor Summit on March 25th
March 23, 2020 13:24 ET
|
Medexus Pharmaceuticals Inc
TORONTO, CHICAGO and MONTREAL, March 23, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today announced that it will be presenting at...
Medexus Provides a Business Update and Outlines Response to COVID-19 Pandemic
March 23, 2020 08:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO, CHICAGO and MONTREAL, March 23, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today provided an update to its shareholders...